October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Hussnain Javaid: New EHA Guidelines for HbSC Disease Management

Hussnain Javaid/LinkedIn

Oct 19, 2026, 16:04

Hussnain Javaid: New EHA Guidelines for HbSC Disease Management

Hussnain Javaid, Consultant Haematologist at NHS UK, Founder of ClinHaem, shared a post on LinkedIn:

”HbSC disease: EHA’s first dedicated guideline is here.

Key updates:

For symptomatic HbSC disease, the guideline suggests choosing between phlebotomy & hydroxyurea, based on the patient’s complications, steady-state Hb, suitability and preference.

Phlebotomy may suit patients with higher Hb—particularly greater than 105 g/L—or the possibility of hyperviscosity-related complications, retinopathy,. Suggested target: Hb 95–105 g/L, with Hb, haematocrit and ferritin monitoring.
Hydroxyurea may suit patients with frequent VOC, recurrent ACS or other severe disease complications.

If response is inadequate, consider combining treatments; exchange transfusion may be considered for severe or progressive complications after specialist review.

Other key recommendations: annual retinal examination from age 10; annual kidney screening from age 10; VTE prophylaxis for admitted patients over 12 unless contraindicated; and transfusion targets based on COMBINED HbS plus HbC.

These are consensus-based recommendations, and HbSC-specific evidence remains limited.”

Hussnain Javaid: New EHA Guidelines for HbSC Disease Management